http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200062721-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4aaf127397fd5f114d8bfee1628e155e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2018-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79f8718c861af42e5636f647df8673a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be0a2efbda1965dc0b843cf0075836e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a024e9b91815ba3a6b3e2f41125fd37 |
| publicationDate | 2020-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200062721-A |
| titleOfInvention | miR-143-3p and miR-373-5p as a marker for diagnosing of anti-cancer drug resistance, and use thereof |
| abstract | The present invention relates to miR-143-3p and miR-373-5p as anticancer drug resistance diagnostic markers, and their use, and specifically, to provide information necessary for diagnosing resistance to anticancer drugs in cancer patients, A method for measuring the expression level of the micro RNA, a pharmaceutical composition for inhibiting resistance to an anticancer agent containing the micro RNA or an analog thereof as an active ingredient, and an anticancer agent for treating a test compound in cells and measuring the expression level of the micro RNA The present invention relates to a method for screening a resistance inhibitor. According to the present invention, it is possible to effectively provide information on whether a cancer patient is resistant to an anti-cancer agent through a method of measuring the expression level of one or more micro RNAs selected from miR-143-3p and miR-373-5p. The use of pharmaceutical compositions according to the invention containing micro RNA or analogs thereof can effectively inhibit resistance to these anticancer agents. In addition, an anticancer drug resistance inhibitor can be effectively screened through a method of screening a substance capable of increasing the expression level of the micro RNA. |
| priorityDate | 2018-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.